18 F‐FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis
The Prostate · 2023
DOI: 10.1002/pros.24559 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2023. Verfasst von Kai Shen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Shanghai Shenkang Hospital Development Center, Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
This study aimed to evaluate the effectiveness of 18 F‐fluoro‐2‐deoxy‐D‐glucose Positron emission tomography/computed tomography ( 18 F‐FDG PET/CT) in predicting prognosis and characterizing the intratumoral glucose uptake of neuroendocrine prostate cancer (NEPC).
Methods
We retrospectively reviewed 189 NEPC patients from two medical centers between January 2009 and April 2021. Of these, 44 patients met the inclusion criteria. The maximum standardized uptake value (SUVmax) was measured to assess the metabolic state of NEPC and comparison were made between different histopathological subtypes. Kaplan–Meier and Cox regression analyses were performed to evaluate the predictive value of SUVmax on overall survival (OS) and progression‐free survival (PFS).
Results
This study analyzed 44 NEPC patients and found that 13 patients had small cell neuroendocrine carcinoma (SCNC), while 31 were diagnosed with adenocarcinoma with neuroendocrine differentiation (Ad‐NED) based on histopathology, and a positive correlation was found between SUVmax and SCNC via Spearman correlation test ( r s = 0.60, p < 0.0001). Furthermore, SUVmax demonstrated good diagnostic accuracy in differentiating SCNC from Ad‐NED (area under the curve 0.88, 95% confidence interval [CI] 0.76–0.99). Kaplan–Meier survival analyses and univariate analyses revealed that patients with SUVmax > 10.2 had a significantly shorter OS than patients with SUVmax ≤ 10.2 (hazard ratio = 4.83, 95% CI 1.45–16.1, p = 0.01).
Conclusions
The histopathological subtypes in NEPC showed a close correlation with the glucose metabolic activity of primary tumors as assessed by 18 F‐FDG PET/CT. High SUVmax values in primary prostate tumors were associated with a worse OS in NEPC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Kai Shen, Minghao Yu, Wei Xue
Förderung
- Shanghai Shenkang Hospital Development Center
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Shen, K., Yu, M., Ji, Y., Zhou, X., Liu, B., Zhang, W., Su, R., Qi, J., Wang, Q., & Xue, W. (2023). 18 F‐FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis. The Prostate. https://doi.org/10.1002/pros.24559
Vancouver
Shen K, Yu M, Ji Y, Zhou X, Liu B, Zhang W, et al. 18 F‐FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis. The Prostate. 2023. doi:10.1002/pros.24559
BibTeX
@article{Shen2023,
author = {Shen, Kai and Yu, Minghao and Ji, Yiyi and Zhou, Xiang and Liu, Bo and Zhang, Weiwei and Su, Ruopeng and Qi, Jun and Wang, Qi and Xue, Wei},
title = {18 F‐FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis},
journal = {The Prostate},
year = {2023},
doi = {10.1002/pros.24559}
}
EUVIMED